|
Forecast Period
|
2024-2028
|
|
Market Size (2022)
|
USD 3.45 billion
|
|
CAGR (2023-2028)
|
8.12%
|
|
Fastest Growing Segment
|
Congenital Growth Hormone Deficiency (GHD) Segment
|
|
Largest Market
|
North America
|
Market Overview
Global Pediatric Growth Hormone Deficiency Market
has valued at USD 3.45 billion in 2022 and is anticipated to project impressive
growth in the forecast period with a CAGR of 8.12% through 2028. The Global
Pediatric Growth Hormone Deficiency (PGHD) Market encompasses a range of
products and services aimed at diagnosing and treating growth hormone
deficiency in pediatric patients. This market plays a crucial role in
addressing growth-related health issues in children and ensuring their optimal
physical development.
Key Market Drivers
Increasing Prevalence of Pediatric Growth Hormone
Deficiency (PGHD)
The increasing prevalence of Pediatric Growth
Hormone Deficiency (PGHD) is a significant market driver for the Global
Pediatric Growth Hormone Deficiency Market. This driver is underpinned by
several factors, all of which have substantial implications for the market. A
substantial portion of PGHD cases can be attributed to genetic factors.
Children with a family history of growth hormone deficiency are at an increased
risk of developing the condition themselves. This genetic link drives the
prevalence of PGHD. As the understanding of genetic factors improves, genetic
testing becomes more prevalent. This results in the identification of more
at-risk individuals, contributing to a growing pool of diagnosed PGHD cases. Premature
birth and low birth weight are risk factors for PGHD. Advances in neonatal care
have increased the survival rates of preterm infants, but they may still face
growth challenges due to hormonal imbalances. With advancements in medical
technology, more premature infants are surviving and receiving medical
attention. This has led to a higher likelihood of identifying growth hormone
deficiencies in this patient group, further increasing the prevalence of PGHD.
Diagnostic tools and techniques have advanced
significantly over the years, enabling more accurate and timely identification
of PGHD cases. These tools include growth charts, blood tests, and imaging
studies. Enhanced diagnostic capabilities mean that cases that might have gone
unnoticed in the past are now being detected. This translates to a higher
number of diagnosed PGHD cases, directly impacting the demand for growth
hormone therapy. Healthcare professionals are becoming more aware of PGHD and
its symptoms. This heightened awareness leads to more comprehensive evaluations
and testing for growth hormone deficiencies in children exhibiting related
symptoms. As healthcare providers become more vigilant in screening for PGHD,
they identify cases that may have previously been overlooked. This proactive
approach contributes to the upward trend in PGHD prevalence.
Advancements in Growth Hormone Therapies
Advancements in Growth Hormone Therapies play a
crucial role as a market driver in the Global Pediatric Growth Hormone
Deficiency (PGHD) Market. These advancements are characterized by innovations
in treatment modalities and formulations, and they significantly impact the
growth and dynamics of the market. Rationale: One major advancement is the
development of long-acting growth hormone formulations. These formulations
allow for less frequent dosing, often just once a week, compared to daily
injections required with traditional therapies. This improves patient
compliance and convenience.
Long-acting formulations enhance the patient
experience, making treatment more manageable and reducing the burden of
frequent injections. As a result, more parents and caregivers opt for growth
hormone therapy, leading to increased market demand. Biosimilars are biologic
drugs that are highly similar to the reference product. They offer a more
cost-effective alternative to branded growth hormone therapies while
maintaining comparable safety and efficacy. The availability of biosimilars in
the market can lead to competitive pricing, making growth hormone therapy more
accessible to a wider patient population. This increased affordability drives
the adoption of treatment and stimulates market growth. Advancements in
genetics and pharmacogenomics have enabled the development of personalized
growth hormone therapies. These treatments are tailored to an individual's
genetic and physiological characteristics, optimizing their response to
therapy. Personalized therapies provide improved treatment outcomes and fewer
side effects, as they are customized to each patient's unique needs. This
encourages healthcare providers to recommend and prescribe growth hormone
therapy more frequently.
Innovations in drug delivery systems have made
administering growth hormone therapies more convenient and less painful. These
systems include needle-free devices, autoinjectors, and wearable infusion
pumps. Patient comfort and ease of administration are significantly improved
with these innovations. Parents and caregivers are more likely to adhere to
treatment plans when they can administer therapy with minimal discomfort,
boosting market demand.
Download Free Sample Report
Growing Healthcare Infrastructure and Access to
Care
The growth of healthcare infrastructure and
improved access to care is a significant market driver for the Global Pediatric
Growth Hormone Deficiency (PGHD) Market. This driver is rooted in various
factors that contribute to the expansion and accessibility of healthcare
services. The construction and expansion of healthcare facilities, including
hospitals, clinics, and specialty centers, contribute to increased access to
medical care. This is particularly relevant for the diagnosis and treatment of
pediatric health conditions, including PGHD.
With more healthcare facilities equipped to
diagnose and manage PGHD, more children have access to specialized care. This
expansion leads to a higher number of diagnosed cases and greater demand for
growth hormone therapy. Governments and organizations worldwide have initiated
programs to improve healthcare access in rural and underserved areas. These initiatives
aim to bridge the gap between urban and rural healthcare services. As rural
communities gain better access to healthcare facilities and services, children
in these areas are more likely to be screened for and diagnosed with PGHD. This
contributes to an increase in the overall prevalence of the condition and
subsequently drives market growth.
Expanding health insurance coverage, both publicly
and privately, ensures that more individuals and families have access to
medical services, including the diagnosis and treatment of PGHD. Health
insurance coverage reduces the financial burden on parents and caregivers when
seeking medical care for their children. This encourages more families to seek
medical attention for suspected growth hormone deficiencies, thereby boosting
market demand. Many governments have introduced healthcare initiatives aimed at
improving child health and well-being. These programs often include early
childhood screenings and access to essential medications. Government-sponsored
healthcare initiatives play a pivotal role in diagnosing and treating PGHD at
an early stage. This leads to timely interventions and a higher prevalence of
diagnosed cases, contributing to market growth.
Heightened Awareness and Patient Advocacy
Heightened awareness and patient advocacy play a
pivotal role as a market driver for the Global Pediatric Growth Hormone
Deficiency (PGHD) Market. These factors are instrumental in increasing the
recognition of PGHD, driving early diagnosis, and promoting the importance of
treatment. Patient advocacy groups, healthcare organizations, and
pharmaceutical companies often collaborate to conduct awareness campaigns and
educational initiatives. These campaigns aim to inform healthcare
professionals, parents, and the general public about PGHD, its signs, symptoms,
and the importance of early intervention.
Increased awareness prompts healthcare providers to
consider PGHD in their differential diagnosis for children with growth issues.
Parents and caregivers are also more likely to seek medical evaluation if they
recognize potential symptoms, leading to earlier diagnosis and treatment
initiation. Patient advocacy groups emphasize the significance of early
diagnosis in PGHD management. They stress the potential benefits of early intervention
in improving a child's growth trajectory and overall health. Heightened
awareness regarding the importance of early diagnosis encourages healthcare
professionals to be proactive in screening for PGHD. As a result, more children
are diagnosed at an earlier stage, increasing the demand for growth hormone
therapy. Patient advocacy groups often collaborate with pharmaceutical
companies and research institutions to support studies and clinical trials
related to PGHD. Their involvement accelerates the development of new treatment
options and therapies. Research and development efforts supported by patient
advocacy groups lead to the introduction of innovative therapies, including
improved growth hormone formulations. These advancements provide additional
treatment options, expanding the market and meeting evolving patient needs.
Key Market Challenges
High Cost of Growth Hormone Therapy
One of the primary challenges is the high cost
associated with growth hormone therapy. These therapies are often expensive,
requiring regular injections over an extended period. The cumulative cost of
treatment can be a significant financial burden for patients and their
families.
The cost barrier can deter some families from
pursuing growth hormone therapy for their children, even when it is medically
necessary. This can limit the market's growth potential, especially in regions
with limited access to health insurance or government-sponsored healthcare
programs.
Regulatory and Approval Hurdles
The development and approval of growth hormone
therapies involve stringent regulatory processes and clinical trials. Meeting
these regulatory requirements can be time-consuming and costly for
pharmaceutical companies. Additionally, obtaining approvals for pediatric
indications may present unique challenges.
Regulatory hurdles can delay the introduction of
new therapies to the market. Delays in approval can limit treatment options for
patients and result in a less competitive landscape, potentially impacting
accessibility and pricing.
Limited Awareness and Diagnosis Challenges
Despite efforts to raise awareness, many cases of
PGHD still go undiagnosed. The condition's symptoms, such as short stature, can
overlap with normal variations in growth, leading to delayed or missed
diagnoses. Additionally, awareness about PGHD may be lower in certain regions.
Limited awareness and diagnosis challenges mean
that a significant number of PGHD cases may remain untreated. This not only
hampers patient outcomes but also restricts the growth of the market, as
undiagnosed cases do not contribute to the demand for growth hormone therapies.
Key Market Trends
Biological and Biosimilar Growth Hormone Therapies:
The trend towards biological and biosimilar growth
hormone therapies is gaining traction in the PGHD market. Biologicals are
produced using living cells and are highly specific to their targets.
Biosimilars are highly similar to already-approved biologicals but may be more
cost-effective.
Biosimilars typically cost less than the original
biologicals, making growth hormone therapy more affordable for patients and
healthcare systems. As more biosimilars enter the market, competition
increases, which can lead to price reductions and increased accessibility. The
availability of biologicals and biosimilars provides physicians with a wider
range of treatment choices, allowing for personalized therapy plans.
Telemedicine and Remote Monitoring:
The adoption of telemedicine and remote monitoring technologies
is becoming a prominent trend in the PGHD market. These technologies enable
healthcare providers to conduct consultations, monitor patients, and manage
treatment remotely.
Telemedicine overcomes geographic barriers,
ensuring that patients in remote or underserved areas can access specialized
PGHD care. Telemedicine enhances the convenience of follow-up appointments and
monitoring, reducing the need for frequent in-person visits. Remote monitoring
tools engage patients and caregivers in managing PGHD, fostering adherence and
facilitating data-driven decision-making.
Personalized Medicine and Genetic Testing:
Personalized medicine and genetic testing are
emerging as influential trends in the PGHD market. These approaches involve
tailoring treatment based on an individual's genetic and physiological
characteristics.
Personalized medicine allows for more precise
treatment, optimizing the therapeutic response and minimizing potential side
effects. Genetic testing can identify specific gene mutations or variations
associated with PGHD, aiding in diagnosis and treatment decisions. Ongoing
research in genomics and pharmacogenomics is driving the development of more
targeted and effective therapies for PGHD.
Segmental Insights
Type Insights
Based on the category of Type, the congenital
growth hormone deficiency (GHD) segment emerged as the dominant player in the
global market for Pediatric Growth Hormone Deficiency in 2022. Congenital GHD, which is present at birth or detected
during early childhood, represents a significant portion of diagnosed cases,
and its prevalence is influenced by various clinical and demographic factors.
Congenital
GHD is characterized by the absence or malfunction of the pituitary gland or
hypothalamus responsible for growth hormone production. This condition often
manifests in infancy or early childhood, leading to earlier diagnosis and
intervention. Early diagnosis allows for prompt initiation of growth hormone
therapy, which is crucial for achieving optimal growth outcomes. Physicians and
caregivers are more likely to identify congenital GHD because of noticeable
growth delays and developmental concerns, driving the dominance of this segment.
Congenital GHD is more prevalent than acquired GHD
in the pediatric population. While acquired GHD can result from factors such as
tumors or radiation therapy, congenital GHD is typically attributed to genetic
or developmental issues. The higher prevalence of congenital GHD naturally
leads to a larger patient population within this segment. A larger patient pool
means greater demand for growth hormone therapy, further solidifying the
dominance of the congenital GHD segment in the market. Congenital GHD often has
genetic underpinnings, and it can run in families. Children born to parents
with a history of GHD or genetic mutations related to growth hormone production
are at a higher risk of developing congenital GHD. Genetic and familial factors
contribute to a consistent influx of diagnosed cases within the congenital GHD
segment. Families with a history of GHD are more likely to seek medical
evaluation for their children if they suspect growth issues, further boosting
the segment's dominance. These factors are expected to drive the growth of this
segment.
Application Insight
Based on the category of Application, the growth
hormone deficiency (GHD) segment emerged as the dominant player in the global
market for Pediatric Growth Hormone Deficiency in 2022. This segment represents
the primary therapeutic approach for addressing pediatric growth hormone
deficiency. Growth hormone therapy is highly effective in stimulating growth
and achieving height gain in children with GHD. Clinical studies and real-world
evidence consistently demonstrate significant improvements in height velocity
and final adult height with GHD treatment. The well-established clinical
effectiveness and high efficacy of growth hormone therapy make it the treatment
of choice for healthcare providers and parents seeking to address PGHD. The
documented success of this application reinforces its dominance in the market.
Growth hormone therapy is not limited to addressing
pediatric GHD alone. It is also indicated for several other conditions,
including Turner syndrome, chronic kidney disease-related growth failure,
Prader-Willi syndrome, and small-for-gestational-age (SGA) children with poor
growth, among others. The broad scope of indications for growth hormone therapy
expands the potential patient population and market demand. Healthcare
providers are more likely to prescribe growth hormone therapy for PGHD
patients, but also for children with related growth disorders, further
strengthening the dominance of the GHD segment.
Growth hormone therapy involves comprehensive
treatment plans that include regular injections, ongoing monitoring, and
adjustments to dosage. This structured approach is essential for maximizing
growth outcomes. The comprehensive nature of growth hormone therapy requires a
long-term commitment from patients, caregivers, and healthcare providers. This
continuity of care ensures that GHD remains the primary application within the
PGHD market. These factors are expected to drive the growth of this segment.
Drug Insight
Based on the category of Drug, the Norditropin
segment emerged as the dominant player in the global market for Pediatric
Growth Hormone Deficiency in 2022. Norditropin is a brand of recombinant human
growth hormone (rhGH) therapy, and it has established itself as a prominent
choice for treating pediatric GHD. Norditropin has a long-standing history of
proven clinical efficacy in stimulating growth and improving height outcomes in
children with GHD. Numerous clinical trials and real-world studies have
consistently demonstrated its effectiveness. The well-established clinical
efficacy of Norditropin instills confidence among healthcare providers,
parents, and caregivers. Its track record as an effective treatment option
solidifies its dominance in the market.
Norditropin offers a range of formulations, including
injectable pens with varying concentrations and delivery options. These
formulations cater to different patient needs, providing flexibility in dosing
and administration. The availability of diverse formulations allows healthcare
providers to tailor treatment plans to individual patients. This versatility
makes Norditropin suitable for a wide range of pediatric GHD cases, enhancing
its market dominance. Norditropin's injectable pens are designed for ease of
use, offering patient-friendly features such as pre-filled cartridges, simple
dose adjustments, and ergonomic designs. These attributes enhance patient
comfort and convenience. Patient-friendly delivery systems encourage better
adherence to treatment regimens, as they reduce the fear and discomfort
associated with injections. This leads to more successful outcomes and
reinforces Norditropin's dominance in the market. These factors collectively
contribute to the growth of this segment.
Distribution Channel Insights
The hospital pharmacies segment is projected to
experience rapid growth during the forecast period. Hospital pharmacies play a
crucial role in ensuring the availability and proper administration of growth
hormone therapy Hospital pharmacies are closely integrated with healthcare
facilities, including pediatric endocrinology departments and pediatric
clinics. Healthcare providers in hospital settings have specialized training
and expertise in diagnosing and managing pediatric GHD. The clinical expertise
of hospital-based healthcare providers ensures the accurate diagnosis of PGHD
and the appropriate prescription of growth hormone therapy. Patients and
caregivers often trust the recommendations and guidance provided by
hospital-based healthcare teams, reinforcing the dominance of hospital pharmacies.
Growth hormone therapy for pediatric GHD often
involves complex treatment regimens, including precise dosing adjustments and
regular monitoring of patient progress. These regimens are best managed in a
clinical setting with the necessary resources and expertise. Hospital
pharmacies are well-equipped to handle the complexities of growth hormone
therapy. They provide a controlled environment for dosage calculations,
administration, and monitoring, reducing the risk of errors. This enhances
patient safety and contributes to the segment's dominance.
Download Free Sample Report
Regional Insights
North America emerged as the dominant player in the
global Pediatric Growth Hormone Deficiencys market in 2022, holding the largest
market share in terms of both value and volume. The United States boasts a
highly advanced healthcare infrastructure, including a robust network of
specialized pediatric hospitals, clinics, and healthcare providers. This
infrastructure allows for comprehensive diagnosis and treatment of PGHD. The
availability of state-of-the-art healthcare facilities and expertise in
pediatric endocrinology makes the United States a dominant player in the PGHD
market. It ensures that a substantial number of PGHD cases are diagnosed and
treated effectively.
The
United States places a strong emphasis on early diagnosis and intervention in
pediatric healthcare. Routine health check-ups and well-child visits enable the
early identification of growth-related issues, including PGHD. The culture of
early diagnosis ensures that a significant proportion of PGHD cases are
identified at a young age, enabling timely interventions with growth hormone
therapy. This proactive approach contributes to the dominance of the region. Health
insurance coverage in the United States, although complex, often includes
coverage for pediatric healthcare needs, including growth hormone therapy. This
reduces financial barriers for many families. Improved access to care, driven
by insurance coverage and financial support, ensures that children with PGHD
have the means to seek diagnosis and treatment. This positively impacts the
prevalence of diagnosed cases and the market's growth.
The
Asia-Pacific market is poised to be the fastest-growing market, offering
lucrative growth opportunities for Pediatric Growth Hormone Deficiency players
during the forecast period. Factors such as The Asia-Pacific region has
experienced rapid economic growth and urbanization, leading to lifestyle
changes and dietary habits that can impact child growth. As a result, there has
been an increase in the prevalence of PGHD in the region. A higher prevalence
of PGHD cases naturally drives the demand for growth hormone therapy in the
APAC region, contributing to market growth. Many countries in the APAC region
have been investing in their healthcare infrastructure, including pediatric
endocrinology departments and specialized clinics. This expansion improves
access to PGHD diagnosis and treatment. Improved healthcare infrastructure
ensures that more children with PGHD can receive proper diagnosis and
treatment, fostering market growth.
Recent Developments
- In August 2023, Novo Nordisk announced that
semaglutide 2.4 mg, a once-weekly injectable GLP-1 receptor agonist, reduced
the risk of major cardiovascular events by 20% in adults with overweight or
obesity who had at least one risk factor for cardiovascular disease.
- Lilly is investing $1.6 billion in the construction
of two new manufacturing facilities in Indiana. The new facilities are expected
to create 200 new jobs and increase Lilly's production capacity for active
pharmaceutical ingredients, including the ingredients for Mounjaro.
- Merck
KGaA is investing USD24.51 million in the expansion of its cell culture media
production facility in Kansas, USA. The company is also investing USD74.60
million in the expansion of its reagent manufacturing facility in Nantong,
China. These investments are expected to increase Merck KGaA's production capacity
for key pharmaceutical ingredients and reagents.
Key Market Players
- Novo
Nordisk A/S
- Eli Lily and Company
- Novartis AG
- Merck KgaA
- Pfizer Inc.
- Ferring B.V
- Genentech Inc
- BioParteners GmbH
- LG Chem Ltd.
- Ipsen Pharma
|
By Type
|
By Product
|
By Application
|
By Drug
|
By Distribution Channel
|
By Region
|
- Congenital
GH Deficiency
- Acquired GH
Deficiency
- Idiopathic
GH Deficiency
|
|
- Growth
Hormone Deficiency
- Idiopathic
Short Stature
- Turner
Syndrome
- Small For
Gestational Age
- Prader-Willi
Syndrome
- Others
|
- Genotropin
- Humatrope
- Norditropin
Flexpro
- Others
|
- Hospital
Pharmacies
- Retail
Pharmacies
- Online
Pharmacies
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Pediatric Growth Hormone
Deficiency Market has been segmented into the following categories, in addition
to the industry trends which have also been detailed below:
- Pediatric Growth Hormone
Deficiency Market, By
Type:
o Congenital GH Deficiency
o Acquired GH Deficiency
o Idiopathic GH Deficiency
- Pediatric Growth Hormone
Deficiency Market, By
Product:
o Powder
o Solvent
- Pediatric Growth Hormone
Deficiency Market, By
Application:
o Growth Hormone Deficiency
o Idiopathic Short Stature
o Turner Syndrome
o Small For Gestational Age
o Prader-Willi Syndrome
o Others
- Pediatric Growth Hormone
Deficiency Market, By
Drug:
o Genotropin
o Humatrope
o Norditropin Flexpro
o Others
- Pediatric Growth Hormone
Deficiency Market, By
Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Others
- Pediatric Growth Hormone
Deficiency Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
§ Turkey
§ Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Pediatric Growth Hormone Deficiency Market.
Available Customizations:
Global Pediatric Growth Hormone Deficiency market
report with the given market data, TechSci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Induration
- Detailed analysis and
profiling of additional market players (up to five).
Global Pediatric Growth Hormone Deficiency Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]